Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

LG Chem Scoops AVEO Oncology At 43% Premium

Published 18/10/2022, 12:36
© Reuters.  LG Chem Scoops AVEO Oncology At 43% Premium

  • South Korea-based LG Chem Ltd has agreed to acquire AVEO Oncology Inc (NASDAQ: AVEO) for $15.00 per share in an all-cash transaction with an implied equity value of $566 million on a fully diluted basis.
  • The transaction price represents a 43% premium to AVEO's closing share price on October 17 and a 71% premium to its 30 trading day volume-weighted average price.
  • The combination of LG Chem's Life Sciences division and AVEO is expected to create a global oncology organization.
  • Through this transaction, AVEO will immediately establish LG Chem's commercial presence in oncology through its lead product, Fotivda (tivozanib), which received FDA approval in March 2021 for relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
  • Upon completion of the transaction, AVEO will establish and operate as the U.S. commercial foundation for LG Chem Life Sciences' oncology segment.
  • The transaction is expected to close in early 2023.
  • LG Chem expects to finance the transaction with existing and available cash resources. Upon completion of the transaction, AVEO's shares will no longer trade on the Nasdaq.
  • Price Action: AVEO shares are up 39% at $14.57 during the premarket session on the last check Tuesday.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.